Document is current
Any future updates will be listed below
-
Authors
Wu, Jun-Long
Jiang, Shu-Suan
Luo, Hong
Dong, Pei
Wang, Zeng-Jun
Xing, Nian-Zeng
Ma, Tao
Wang, Zhi-Ping
Gu, Xin-Quan
Zhou, Guang-Chen
Xue, Xue-Yi
Sun, Zhong-Quan
Yang, Yong
Wang, Chun-Xi
Shan, Guang-Yi
Zhang, Ai-Li
Ding, De-Gang
Wang, Li-Ping
Duan, Xiao-Hui
Wang, Ting-Ting
He, Ting
Lin, Chao-Yu
Zhong, Xin-Wei
Lian, Jian-Po
Wang, Wen-Liang
Ye, Ding-Wei
Dai, Bo
-
Funding
Funding for this research was provided by:
Jiangsu Hengrui Pharmaceuticals Co., Ltd
- License Information
-
More Information
Article History
Received: 9 December 2025
Accepted: 5 June 2026
First Online: 30 June 2026
Declarations
Ethics approval and consent to participate: The protocol and all amendments were approved by the Fudan University Shanghai Cancer Center Institutional Review Board (approval number: 1802181-1) and the independent ethics committees of all participating institutions. Written informed consent was obtained from all patients before initiation of study treatment.
Consent for publication: Not applicable.
Competing interests: The authors declare no competing interests.
